BTIG Believes OXFD Won’t Stop Here

By Jason Carr

BTIG analyst Karen Koski reiterated a Buy rating on Oxford Immunotec (NASDAQ: OXFD) on March 7 and set a price target of $19. The company’s shares closed yesterday at $14.96, close to its 52-week high of $15.76.

According to, Koski is a 5-star analyst with an average return of 12.9% and a 66.7% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

Oxford Immunotec has an analyst consensus of Moderate Buy, with a price target consensus of $19.

The company has a one year high of $15.76 and a one year low of $7.73. Currently, Oxford Immunotec has an average volume of 93.98K.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oxford Immunotec Global Plc is a medical diagnostics company, which engages in the provisions of innovative tests in the field of immunology. It provides T-SPOT technology to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.